These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 27789778)

  • 1. A Phase I Study of the Safety and Pharmacokinetics of Higher-Dose Icotinib in Patients With Advanced Non-Small Cell Lung Cancer.
    Liu J; Wu L; Wu G; Hu X; Zhou H; Chen J; Zhu M; Xu W; Tan F; Ding L; Wang Y; Shentu J
    Oncologist; 2016 Nov; 21(11):1294-1295d. PubMed ID: 27789778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors.
    Zhao Q; Shentu J; Xu N; Zhou J; Yang G; Yao Y; Tan F; Liu D; Wang Y; Zhou J
    Lung Cancer; 2011 Aug; 73(2):195-202. PubMed ID: 21144613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC).
    Hu X; Han B; Gu A; Zhang Y; Jiao SC; Wang CL; He J; Jia X; Zhang L; Peng J; Wu M; Ying K; Wang J; Ma K; Zhang S; You C; Tan F; Wang Y; Ding L; Sun Y
    Lung Cancer; 2014 Nov; 86(2):207-12. PubMed ID: 25261231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between icotinib hydrochloride exposure and clinical outcome in Chinese patients with advanced non-small cell lung cancer.
    Ni J; Liu DY; Hu B; Li C; Jiang J; Wang HP; Zhang L
    Cancer; 2015 Sep; 121 Suppl 17():3146-56. PubMed ID: 26331821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of whole brain radiation therapy on CSF penetration ability of Icotinib in EGFR-mutated non-small cell lung cancer patients with brain metastases: Results of phase I dose-escalation study.
    Zhou L; He J; Xiong W; Liu Y; Xiang J; Yu Q; Liang M; Zhou X; Ding Z; Huang M; Ren L; Zhu J; Li L; Hou M; Ding L; Tan F; Lu Y
    Lung Cancer; 2016 Jun; 96():93-100. PubMed ID: 27133757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of icotinib in Chinese patients with advanced non-small cell lung cancer after failure of chemotherapy.
    Shao L; Zhang B; He C; Lin B; Song Z; Lou G; Yu X; Zhang Y
    Chin Med J (Engl); 2014; 127(2):266-71. PubMed ID: 24438614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of icotinib on advanced non-small cell lung cancer with different EGFR phenotypes.
    Pan H; Liu R; Li S; Fang H; Wang Z; Huang S; Zhou J
    Cell Biochem Biophys; 2014 Sep; 70(1):553-8. PubMed ID: 24777808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial.
    Shi Y; Zhang L; Liu X; Zhou C; Zhang L; Zhang S; Wang D; Li Q; Qin S; Hu C; Zhang Y; Chen J; Cheng Y; Feng J; Zhang H; Song Y; Wu YL; Xu N; Zhou J; Luo R; Bai C; Jin Y; Liu W; Wei Z; Tan F; Wang Y; Ding L; Dai H; Jiao S; Wang J; Liang L; Zhang W; Sun Y
    Lancet Oncol; 2013 Sep; 14(10):953-61. PubMed ID: 23948351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in Chinese patients with non-small cell lung cancer.
    Wang HP; Zhang L; Wang YX; Tan FL; Xia Y; Ren GJ; Hu P; Jiang J; Wang MZ; Xiao Y
    Chin Med J (Engl); 2011 Jul; 124(13):1933. PubMed ID: 22088449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of icotinib in treating non-small cell lung cancer: a systematic evaluation and meta-analysis based on 15 studies.
    Biaoxue R; Hua L; Wenlong G; Shuanying Y
    Oncotarget; 2016 Dec; 7(52):86902-86913. PubMed ID: 27893423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective study of adjuvant icotinib in postoperative lung cancer patients harboring epidermal growth factor receptor mutations.
    Yao S; Zhi X; Wang R; Qian K; Hu M; Zhang Y
    Thorac Cancer; 2016 Sep; 7(5):543-548. PubMed ID: 27766784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized Adjuvant Chemotherapy of EGFR-Mutated Non-Small Cell Lung Cancer Patients with or without Icotinib Consolidation Therapy.
    Feng S; Wang Y; Cai K; Wu H; Xiong G; Wang H; Zhang Z
    PLoS One; 2015; 10(10):e0140794. PubMed ID: 26474174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial.
    Yang JJ; Zhou C; Huang Y; Feng J; Lu S; Song Y; Huang C; Wu G; Zhang L; Cheng Y; Hu C; Chen G; Zhang L; Liu X; Yan HH; Tan FL; Zhong W; Wu YL
    Lancet Respir Med; 2017 Sep; 5(9):707-716. PubMed ID: 28734822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical pharmacokinetics, safety, and preliminary efficacy evaluation of icotinib in patients with advanced non-small cell lung cancer.
    Liu D; Zhang L; Wu Y; Jiang J; Tan F; Wang Y; Liu Y; Hu P
    Lung Cancer; 2015 Sep; 89(3):262-7. PubMed ID: 26162563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy of icotinib for advanced non-small cell lung cancer patients with EGFR status identified].
    Song Z; Yu X; Cai J; Shao L; Lin B; He C; Zhang B; Zhang Y
    Zhongguo Fei Ai Za Zhi; 2013 Mar; 16(3):138-43. PubMed ID: 23514942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical Observation of Icotinib Hydrochloride for Advanced Non-small Cell Lung Cancer Patients with EGFR Status Identified].
    Li X; Qin N; Wang J; Yang X; Zhang X; Lv J; Wu Y; Zhang H; Nong J; Zhang Q; Zhang S
    Zhongguo Fei Ai Za Zhi; 2015 Dec; 18(12):734-9. PubMed ID: 26706949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China.
    Lu S; Ye M; Ding L; Tan F; Fu J; Wu B
    Oncotarget; 2017 Feb; 8(6):9996-10006. PubMed ID: 28036283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Icotinib: activity and clinical application in Chinese patients with lung cancer.
    Guan YS; He Q; Li M
    Expert Opin Pharmacother; 2014 Apr; 15(5):717-28. PubMed ID: 24588695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4).
    Murakami H; Tamura T; Takahashi T; Nokihara H; Naito T; Nakamura Y; Nishio K; Seki Y; Sarashina A; Shahidi M; Yamamoto N
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):891-9. PubMed ID: 22071596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacokinetics of Icotinib, an anti-cancer drug: evaluation of dose proportionality, food effect, and tolerability in healthy subjects.
    Liu D; Jiang J; Zhang L; Tan F; Wang Y; Zhang D; Hu P
    Cancer Chemother Pharmacol; 2014 Apr; 73(4):721-7. PubMed ID: 24488324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.